Method for establishing in-vitro diabetic cataract organ model

By using pluripotent stem cell differentiation technology in vitro to construct a diabetic cataract organoid model, the problem of lack of effective in vitro models in the existing technology is solved, and reliable research tools and drug screening platform is provided, which simulates the pathogenesis of diabetic cataracts and The degree of turbidity is controlled.

CN119082028APending Publication Date: 2024-12-06ZHEJIANG UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411207321.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The lack of effective in vitro diabetic cataract research models in the prior art has made it difficult to conduct intervention tests for early diabetic cataracts, and there are large differences between in vivo animal models and in vitro cell line models, making it difficult to accurately simulate human disease processes.

Method used

By inducing differentiation into primary lens bodies using pluripotent stem cells in vitro and adding growth factors and glucose to specific culture media, it simulates the formation environment of diabetic cataracts and differentiates into mature lens bodies, and finally builds a diabetic that meets specific standards. Cataract organoid model.

Benefits of technology

A 3D in vitro model that is morphologically and structurally close to human diabetic cataracts is successfully constructed, providing reliable research tools to simulate the onset process and allow drug screening, and the degree of turbidity can be controlled by incubation time and glucose concentration.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005019390550000011
    Figure HDA0005019390550000011
  • Figure HDA0005019390550000012
    Figure HDA0005019390550000012
  • Figure HDA0005019390550000021
    Figure HDA0005019390550000021
Patent Text Reader

Abstract

The invention discloses a method for establishing an in-vitro diabetic cataract organ model, and the in-vitro diabetic cataract organ model provided by the invention is provided by a crystalline lens organ induced by pluripotent stem cells. The hyperglycemia environment where the crystalline lens of a diabetic patient is located is simulated by adding different concentrations of diabetic cataract special inducible factors in vitro. The in-vitro diabetic cataract organ model obtained by the method can be used for researching the pathogenesis of diabetic cataract, can screen drugs for relieving and / or treating diabetic cataract in vitro, and can better simulate the process that in-vivo crystalline lenses develop into cataract in a high-glucose environment compared with an in-vitro cell line model; the provided special three-dimensional culture medium is added with special induction factors of diabetic cataract, has the characteristics of no serum, definite chemical components, simplicity, easiness in operation and the like, and is more suitable for induction of an in-vitro diabetic cataract model.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of organoid model construction, and in particular relates to a method for establishing an in vitro diabetic cataract organoid model. Background Art

[0002] Diabetic cataract is a blinding eye disease caused by impaired glucose metabolism in diabetic patients, which leads to lens opacity. It is generally believed that the pathogenesis of diabetic cataract is due to the increase in blood sugar concentration caused by relative or absolute lack of insulin in the body, which increases the amount of glucose entering the lens. The increased glucose in the lens is activated by the polyol bypass and converted into sorbitol, which is deposited in the cells, increasing the osmotic pressure of the cells and causing the lens fibers to absorb water and swell, thus leading to lens opacity. Diabetic cataract is one of the common complications of diabetes and can be divided into true diabetic cataract and combined senile cortical cataract. The former is more common in juvenile diabetic patients with type I diabetes, and it develops rapidly and can develop into complete cataract in a short period of time; while the latter is more common in elderly patients. Compared with simple senile cortical cataract, it develops earlier, progresses faster, and has a greater impact on vision. Currently, the main treatment for diabetic cataracts is to control primary hyperglycemia and perform surgical treatment for advanced cataracts. However, for early diabetic cataracts that are already mildly turbid, there is still a lack of effective intervention methods except for controlling blood sugar. The reason is the lack of research models for diabetic cataracts, which makes it difficult to carry out a series of intervention trials for early diabetic cataracts.

[0003] The in vivo animal models for studying diabetic cataracts are mainly focused on experimental animals such as mice and New Zealand rabbits, and there are still species differences in the development process of diabetic cataracts in humans; while the in vitro models are still at the cell line level, and their single-layer 2D culture form is also quite different from the real cell environment, genetic background and functional characteristics of the normal human lens. Due to the limitations of animal models and in vitro cell line model research, there is an urgent need for an effective and reliable in vitro diabetic cataract research model to effectively study its microscopic pathogenesis and the screening of targeted drug molecules.

[0004] In recent years, with the development of organoid technology, the construction of organoid models in vitro, the study of the mechanisms of diseases caused by the structural and functional disorders of the organs they represent, and the screening of related therapeutic drugs have opened up new ideas for the in vitro study of diseases. At present, China has been able to induce transparent lens bodies with a maximum diameter of 3mm through pluripotent stem cells. On this basis, the construction of an in vitro model of senile cataracts has been completed, and related drug screening has been carried out. However, there has been no report on an in vitro model related to diabetic cataracts. Summary of the invention

[0005] In view of the lack of in vitro models related to diabetic cataracts, the purpose of the present invention is to provide a method for constructing an in vitro diabetic cataract organoid model. This method can simulate the development process of diabetic cataracts in vitro and provide a reliable research tool for further studying the pathogenesis of diabetic cataracts and screening of diabetic cataract-related drugs.

[0006] To achieve the above object, the present invention provides the following technical solution: a method for establishing an in vitro diabetic cataract organoid model, comprising the following steps:

[0007] (1) using a method for inducing differentiation of pluripotent stem cells in a culture dish to culture induced pluripotent stem cells into primary lens bodies;

[0008] (2) In the culture dish, according to the inclusion criteria of primary lens body organoids, primary lens bodies that meet the inclusion criteria are selected for retention, and primary lens bodies that do not meet the inclusion criteria are separated;

[0009] Then determine whether the density of the primary lens bodies retained in the culture dish is between 10 and 15 / 9.6 cm 2 : If between 10 and 15 pieces / 9.6 cm 2 , continue to culture the retained primary lens bodies for 9 to 11 days using mTesR medium containing bFGF and Wnt3a to allow the primary lens bodies to differentiate into mature lens bodies; otherwise, return to step (1) for re-induction;

[0010] (3) Then, mTesR medium containing glucose was added to induce mature lens bodies, and the mTesR medium containing glucose was replaced every day. After 10 to 15 days of induction, the diabetic opacified lens bodies were retained as the in vitro diabetic cataract organoid model according to the inclusion criteria of the diabetic cataract organoid model, and the mature lens bodies that did not meet the criteria were removed with a sterile needle.

[0011] Furthermore, in step (2), the inclusion criteria of the primary lens organoids are: 1) presenting a transparent 3D structure; 2) having a complete, uniform, and continuous border; 3) being round or oval in shape; 4) having a diameter of 1 to 3 mm; and 5) having no turbid cell clusters around.

[0012] Furthermore, in step (2), the mTesR culture medium contains 80-120 ng / ml of bFGF and 17-23 ng / ml of Wnt3a.

[0013] Furthermore, the mTesR culture medium contains 5-25 mM glucose.

[0014] Furthermore, the inclusion criteria of the diabetic cataract organoid model are: 1) round or oval in shape; 2) having complete, uniform, and continuous boundaries; 3) a diameter of 1 to 3 mm; 4) the average optical density value of the turbid area measured using Image J is greater than 0.266.

[0015] The beneficial effects of the present invention are:

[0016] 1) The present invention simulates the in vivo diabetic cataract formation environment by using a special diabetic cataract culture medium composed of different growth factors, breaking through the limitations of the previous 2D cell line model, and obtaining a 3D diabetic cataract organoid model cultured in vitro that is closer to human diabetic cataract in morphology and structure;

[0017] 2) Based on the diabetic cataract organoid model provided by the above technical solution, human pluripotent stem cells can be used to simulate the pathogenesis of human diabetic cataract in vitro, and an in vitro diabetic cataract organoid model and a drug treatment screening model can be established;

[0018] 3) The present invention constructs a new model of diabetic cataract organoids, so that the established organ damage model is stable, the induced lens opacity is appropriate, and the degree of opacity can be controlled by the culture time and the added glucose concentration. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 The morphology of lens bodies in mTesR medium without glucose and with 5mM and 25mM glucose added respectively under a 4x microscope is shown;

[0020] Figure 2 This is a DiOC6 immunofluorescence staining image of the in vitro diabetic cataract organoid model;

[0021] Figure 3 This is an immunofluorescence staining image of the expression of collagen-IV and E-cadherin between lens epithelial cells in an in vitro diabetic cataract organoid model;

[0022] Figure 4 This is an immunofluorescence staining image of the expression results of diabetes-related indicators N(ε)-carboxymethyllysine (CML) and aldose reductase AKR1B1 in the diabetic cataract organoid model;

[0023] Figure 5 Graph of mean optical density values ​​obtained for the diabetic cataract organoid model for 5 mM and 25 mM treatments measured using Image J software. DETAILED DESCRIPTION

[0024] In order to make the purpose, technical scheme and advantages of the present invention more clear, the present invention is further described in detail in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention, rather than all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0025] In view of the lack of in vitro models related to diabetic cataracts, the purpose of the present invention is to provide a method for constructing an in vitro diabetic cataract organoid model. This method can simulate the development process of diabetic cataracts in vitro and provide a reliable research tool for further studying the pathogenesis of diabetic cataracts and screening of diabetic cataract-related drugs.

[0026] The experimental methods described in the following examples are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.

[0027] The present invention provides a method for establishing an in vitro diabetic cataract organoid model, comprising the following steps:

[0028] (1) Induced pluripotent stem cells are cultured into primary lens corpuscles in a culture dish using the method for inducing differentiation of pluripotent stem cells provided in Chinese patent CN105238737A "A novel method for directing differentiation of induced pluripotent stem cells into lens corpuscles in vitro" to induce differentiation of pluripotent stem cells into primary lens corpuscles.

[0029] (2) In the culture dish, according to the inclusion criteria for primary lens body organoids, select the primary lens bodies that meet the inclusion criteria for primary lens body organoids on days 18 to 24 of induced pluripotent stem cells and retain them, and carefully separate the primary lens bodies that do not meet the inclusion criteria for primary lens body organoids with a sterile needle, remove them with a pipette, and rinse them with sterile PBS.

[0030] Then determine whether the density of the primary lens bodies retained in the culture dish is between 10 and 15 / 9.6 cm 2 In this embodiment, the density is 10 to 15 pieces / 9.6 cm 2 The retained primary lens bodies are cultured for 9 to 11 days in mTesR medium containing 80 to 120 ng / ml bFGF and 17 to 23 ng / ml Wnt3a to allow the primary lens bodies to differentiate into mature lens bodies; otherwise, return to step (1) for re-induction.

[0031] The inclusion criteria for the primary lens corpuscle organoids are: 1) presenting a transparent 3D structure; 2) having a complete, uniform, and continuous border; 3) being round or oval in shape; 4) having a diameter of 1 to 3 mm; 5) having no turbid cell clusters around. Only when the above five conditions are met at the same time can they be regarded as the retained primary lens corpuscles.

[0032] (3) Subsequently, mTesR medium containing 5-25 mM glucose was added to induce mature lens bodies, and the mTesR medium containing glucose was replaced every day. After 10-15 days of induction, the diabetic opacified lens bodies were retained as the in vitro diabetic cataract organoid model according to the inclusion criteria of the diabetic cataract organoid model, and the mature lens bodies that did not meet the criteria were removed with a sterile needle.

[0033] The inclusion criteria for the diabetic cataract organoid model are: 1) round or oval in shape; 2) with complete, uniform, and continuous boundaries; 3) 1 to 3 mm in diameter; 4) the average optical density of the turbid area measured by Image J is greater than 0.266. Among them, lens bodies with an average optical density value ≥ 0.29 are classified as severe diabetic cataract organoid models.

[0034] Example 1

[0035] A method for establishing an in vitro diabetic cataract organoid model, comprising the following steps:

[0036] (1) Induced pluripotent stem cells are cultured into primary lens corpuscles in a culture dish using the method for inducing differentiation of pluripotent stem cells provided in Chinese patent CN105238737A "A novel method for directing differentiation of induced pluripotent stem cells into lens corpuscles in vitro" to induce differentiation of pluripotent stem cells into primary lens corpuscles.

[0037] (2) In the culture dish, according to the inclusion criteria for primary lens body organoids, on the 18th day of induced pluripotent stem cells, primary lens bodies that meet the inclusion criteria for primary lens body organoids are selected and retained, and primary lens bodies that do not meet the inclusion criteria are carefully separated with a sterile needle, removed with a pipette tip, and rinsed with sterile PBS.

[0038] Then determine whether the density of the primary lens bodies retained in the culture dish is between 10 and 15 / 9.6 cm 2 In this embodiment, the density is 10 to 15 pieces / 9.6 cm 2 The retained primary lens bodies were cultured for 9 days in mTesR medium containing 80 ng / ml bFGF and 17 ng / ml Wnt3a to allow the primary lens bodies to differentiate into mature lens bodies; otherwise, the cells were returned to step (1) for re-induction.

[0039] (3) Subsequently, mTesR medium containing 5 mM glucose was added to induce mature lens bodies, and the mTesR medium containing glucose was replaced every day. After 15 days of induction, the diabetic opacified lens bodies were retained as the in vitro diabetic cataract organoid model according to the inclusion criteria of the diabetic cataract organoid model, and the mature lens bodies that did not meet the criteria were removed with a sterile needle.

[0040] Example 2

[0041] A method for establishing an in vitro diabetic cataract organoid model, comprising the following steps:

[0042] (1) Induced pluripotent stem cells are cultured into primary lens corpuscles in a culture dish using the method for inducing differentiation of pluripotent stem cells provided in Chinese patent CN105238737A "A novel method for directing differentiation of induced pluripotent stem cells into lens corpuscles in vitro" to induce differentiation of pluripotent stem cells into primary lens corpuscles.

[0043] (2) In the culture dish, according to the inclusion criteria of primary lens body organoids, on the 20th day of induced pluripotent stem cells, primary lens bodies that meet the inclusion criteria of primary lens body organoids are selected and retained, and primary lens bodies that do not meet the inclusion criteria are carefully separated with a sterile needle, removed with a pipette tip, and rinsed with sterile PBS.

[0044] Then determine whether the density of the primary lens bodies retained in the culture dish is between 10 and 15 / 9.6 cm 2 In this embodiment, the density is 10 to 15 pieces / 9.6 cm 2 The retained primary lens bodies were cultured for 10 days in mTesR medium containing 100 ng / ml bFGF and 20 ng / ml Wnt3a to allow the primary lens bodies to differentiate into mature lens bodies; otherwise, the process returned to step (1) for re-induction.

[0045] (3) Subsequently, mTesR medium containing 25 mM glucose was added to induce mature lens bodies, and the mTesR medium containing glucose was replaced every day. After 10 days of induction, the diabetic turbid lens bodies were retained as the in vitro diabetic cataract organoid model according to the inclusion criteria of the diabetic cataract organoid model, and the mature lens bodies that did not meet the criteria were removed with a sterile needle.

[0046] Example 3

[0047] A method for establishing an in vitro diabetic cataract organoid model, comprising the following steps:

[0048] (1) Induced pluripotent stem cells are cultured into primary lens corpuscles in a culture dish using the method for inducing differentiation of pluripotent stem cells provided in Chinese patent CN105238737A "A novel method for directing differentiation of induced pluripotent stem cells into lens corpuscles in vitro" to induce differentiation of pluripotent stem cells into primary lens corpuscles.

[0049] (2) In the culture dish, according to the inclusion criteria of primary lens body organoids, on the 24th day of induced pluripotent stem cells, primary lens bodies that meet the inclusion criteria of primary lens body organoids are selected and retained, and primary lens bodies that do not meet the inclusion criteria are carefully separated with a sterile needle, removed with a pipette, and rinsed with sterile PBS.

[0050] Then determine whether the density of the primary lens bodies retained in the culture dish is between 10 and 15 / 9.6 cm 2 In this embodiment, the density is 10 to 15 pieces / 9.6 cm 2 The retained primary lens bodies were cultured for 10 days in mTesR medium containing 120 ng / ml bFGF and 23 ng / ml Wnt3a to allow the primary lens bodies to differentiate into mature lens bodies; otherwise, the cells were returned to step (1) for re-induction.

[0051] (3) Subsequently, mTesR medium containing 15 mM glucose was added to induce mature lens bodies, and the mTesR medium containing glucose was replaced every day. After 8 days of induction, the diabetic opacified lens bodies were retained as the in vitro diabetic cataract organoid model according to the inclusion criteria of the diabetic cataract organoid model, and the mature lens bodies that did not meet the criteria were removed with a sterile needle.

[0052] Obtained in vitro diabetic cataract organoid model

[0053] Figure 1 The figure shows the morphology of lens bodies in mTesR medium without additional glucose and with 5mM and 25mM glucose added respectively under a 4x microscope. Figure 1 As shown in the figure, the obtained in vitro diabetic cataract organoid model presents a turbid 3D structure, which is round or nearly round with a diameter of about 1-3 mm. On the 35th day (D35) of culture from induced pluripotent stem cells, compared with the mature lens bodies in the control group without adding glucose to the mTesR medium, the central part of the lens bodies cultured after adding glucose to the mTesR medium was more turbid; and when the glucose concentration in the mTesR medium was 25mM, the lens bodies began to become significantly turbid from the 30th day (D30) of culture from induced pluripotent stem cells.

[0054] DiOC6 immunofluorescence staining of in vitro diabetic cataract organoid model (see Figure 2 )

[0055] Dissolve DiOC6 (Sigma-Aldrich) in DMSO to prepare a working solution. Add the DiOC6 working solution to the cell culture medium and gently stir to ensure that all cells are covered. Incubate at 37°C in the dark for 20 minutes, wash three times with PBS for 5 minutes each, and aspirate to remove unbound dye. Observe the cells using a fluorescence microscope. DiOC6 will emit green fluorescence under blue light excitation.

[0056] Figure 2 This is a DiOC6 immunofluorescence staining image of an in vitro diabetic cataract organoid model, showing the proliferation of the lens fiber cell membrane structure in the in vitro diabetic cataract organoid model. Figure 2 As shown, DiOC6 fluorescence staining showed that the endoplasmic reticulum, vesicle membrane and mitochondria of the central zone fiber cells in the obtained in vitro diabetic cataract organoid model were clearly stained, indicating that their organelles had not degenerated and the cells were irregularly arranged.

[0057] Immunofluorescence staining of the expression of collagen-IV, E-cadherin, diabetes-related indicator N(ε)-carboxymethyllysine (CML) and aldose reductase AKR1B1 in the in vitro diabetic cataract organoid model (see Figure 3 , Figure 4 )

[0058] The culture medium of the in vitro diabetic cataract organoid model was aspirated, washed three times with PBS, and aspirated. Fix with 4% (M / V) PFA (purchased from Sigma) solution at room temperature for 15 minutes, aspirate PFA, wash three times with PBS, 5 minutes each time, and aspirate. Treat with 0.4% (V / V) Triton X (in PBS) for 15 minutes to penetrate the cell membrane, and wash three times with 0.1% Triton X (in PBS), 5 minutes each time. Block with 10% (V / V) goat serum (in 0.1% Triton X) at room temperature for 1 hour, shaking at low speed. Add the corresponding primary antibody diluted with 0.1% Triton X (all purchased from Santa Cruz Biotechnology) to the cell sample and place it in a humidified box at 4°C overnight. After overnight, wash three times with 0.1% Triton X, 5 minutes each time, and aspirate. Add the secondary antibody diluted with 0.1% Triton X (purchased from Cell Signaling Technology) to the cell sample and shake at low speed for 1 hour in the dark. Wash three times with 0.1% Triton X, 5 minutes each time, and then dry; add 5ug / ml DAPI (purchased from Bio-Tech) and stain for 5 minutes with low-speed shaking in the dark. Wash three times with PBS, 5 minutes each time, and then dry and add PBS to prevent the cells from drying. Observe under an inverted fluorescence microscope.

[0059] Figure 3 This is an immunofluorescence staining of the expression of collagen-IV and E-cadherin between lens epithelial cells in an in vitro diabetic cataract organoid model. Figure 3 As shown, the uniformity and continuity of the expression of the capsule marker collagen-IV and the epithelial marker E-cadherin in the in vitro diabetic cataract organoid model were weakened, suggesting that the capsule and epithelial tissue structure of the lens organoids were disordered.

[0060] Figure 4 This is an immunofluorescence staining image of the expression results of diabetes-related indicators N(ε)-carboxymethyllysine (CML) and aldose reductase AKR1B1 in the diabetic cataract organoid model. Figure 4 As shown, compared with mature lens bodies without glucose induction, the expression of aldose reductase AKR1B1 and advanced glycation end products (AGEs) indicator protein N(ε)-carboxymethyllysine (CML) in the central region of the lens bodies in this model was increased.

[0061] Figure 5The average optical density value (IOD / Area) of the diabetic cataract organoid model obtained by 5mM and 25mM treatment using Image J software (the sample size of each group is 36-44, *P<0.05, **P<0.01) Figure 5 As shown, the average optical density value (IOD / Area) of the obtained diabetic cataract organoid model was measured using Image J (sample size n≥33 in each group). According to the correspondence between the degree of opacity and the average optical density value, lens bodies with an average optical density value ≥0.266 were included in the diabetic cataract organoid model, among which lens bodies with an average optical density value ≥0.29 were classified as severe diabetic cataract organoid models.

[0062] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A method for establishing an in vitro diabetic cataract organoid model, characterized in that: The following steps are involved: (1) using a method for inducing differentiation of pluripotent stem cells in a culture dish to culture induced pluripotent stem cells into primary lens bodies; (2) In the culture dish, according to the inclusion criteria of primary lens body organoids, primary lens bodies that meet the inclusion criteria are selected for retention, and primary lens bodies that do not meet the inclusion criteria are separated; Then determine whether the density of the primary lens bodies retained in the culture dish is between 10 and 15 / 9.6 cm 2 : If between 10 to 15 pieces / 9.6cm 2 , continue to culture the retained primary lens bodies for 9 to 11 days using mTesR medium containing bFGF and Wnt3a to allow the primary lens bodies to differentiate into mature lens bodies; otherwise, return to step (1) for re-induction; (3) Then, mTesR medium containing glucose was added to induce mature lens bodies, and the mTesR medium containing glucose was replaced every day. After 10 to 15 days of induction, the diabetic opacified lens bodies were retained as the in vitro diabetic cataract organoid model according to the inclusion criteria of the diabetic cataract organoid model, and the mature lens bodies that did not meet the criteria were removed with a sterile needle.

2. The method for establishing an in vitro diabetic cataract organoid model according to claim 1, characterized in that: In step (2), the inclusion criteria of the primary lens organoids are: 1) presenting a transparent 3D structure; 2) having a complete, uniform, and continuous border; 3) being round or oval in shape; 4) having a diameter of 1 to 3 mm; and 5) having no turbid cell clusters around.

3. The method for establishing an in vitro diabetic cataract organoid model according to claim 1, characterized in that: In step (2), the mTesR culture medium contains 80-120 ng / ml of bFGF and 17-23 ng / ml of Wnt3a.

4. The method for establishing an in vitro diabetic cataract organoid model according to claim 1, characterized in that: In step (3), the mTesR culture medium contains 5-25 mM glucose.

5. The method for establishing an in vitro diabetic cataract organoid model according to claim 1, characterized in that: In step (3), the inclusion criteria of the diabetic cataract organoid model are: 1) round or oval in shape; 2) having complete, uniform, and continuous boundaries; 3) a diameter of 1 to 3 mm; 4) the average optical density value of the turbid area measured using Image J is greater than 0.266.

Citation Information

Patent Citations

  • Novel method for inducing pluripotent stem cells to directionally differentiate into in-vitro crystalline lenses

    CN105238737A